Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Depreciation and Depletion (2019 - 2023)

Historic Depreciation and Depletion for Benitec Biopharma (BNTC) over the last 5 years, with Q3 2023 value amounting to $19000.0.

  • Benitec Biopharma's Depreciation and Depletion fell 5476.19% to $19000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $121000.0, marking a year-over-year decrease of 2292.99%. This contributed to the annual value of $167000.0 for FY2022, which is 2770.56% down from last year.
  • Per Benitec Biopharma's latest filing, its Depreciation and Depletion stood at $19000.0 for Q3 2023, which was down 5476.19% from $42000.0 recorded in Q3 2022.
  • Benitec Biopharma's Depreciation and Depletion's 5-year high stood at $67000.0 during Q4 2020, with a 5-year trough of $6000.0 in Q2 2022.
  • Its 5-year average for Depreciation and Depletion is $46357.1, with a median of $51000.0 in 2019.
  • In the last 5 years, Benitec Biopharma's Depreciation and Depletion skyrocketed by 3958.33% in 2021 and then plummeted by 8846.15% in 2022.
  • Benitec Biopharma's Depreciation and Depletion (Quarter) stood at $51000.0 in 2019, then soared by 31.37% to $67000.0 in 2020, then dropped by 17.91% to $55000.0 in 2021, then decreased by 23.64% to $42000.0 in 2022, then plummeted by 54.76% to $19000.0 in 2023.
  • Its Depreciation and Depletion was $19000.0 in Q3 2023, compared to $42000.0 in Q3 2022 and $6000.0 in Q2 2022.